Answers are grounded in this paper and cite their sources.
A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to be safe and immunogenic 28 days post-vaccination. Among the original 1800 study participants, a subset of 786 was further evaluated for immune responses by rabbit complement serum bactericidal assay (rSBA) at 6 and 12 months after immunization. At 12 months post-immunization, 100% of NmCV-5 group retained titers ≥128 for serogroups A, Y, and W, 99.8% for X and 90.9% for serogroup C. For the MenACYW-D group, 100% retained titers ≥128 for A, 99.6% for Y, 98.1% for W, 74.8% for serogroup C, and 89.9% for X. The seroresponse rate in the NmCV-5 group was 58% for A, 91.5% for Y, 96.4% for W, 82.6% for X and 89.8% for C. In the MenACYW-D group, the seroresponse rate was 37.6% for A, 86.1% for Y, 92.7% for W, 75.5% for C, and 7.1% for X. Geometric mean titers (GMTs) declined between 28 days and 12 months. At 12 months, in the NmCV-5 group they were at 985 for C and >4096 for all other serogroups. In the MenACYW-D group, GMTs were 269 for C, >2048 for A, W, Y and remained at baseline levels for X. Further investigation is needed at later timepoints to project NmCV-5 duration of protection.
No takes yet. Share an insight, caveat, or question.
Martellet et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: